Ocular Melanoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: OCL022 MIFTS: 50	Ocular Melanoma Categories: Cancer diseases, Neuronal diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Ocular Melanoma

MalaCards integrated aliases for Ocular Melanoma:

Name: Ocular Melanoma ¹² ⁷⁴ ⁵² ⁵⁴ ¹⁵ ¹⁷

Intraocular Melanoma ¹² ⁵²

Malignant Melanoma of Eye ⁷¹

Melanoma of the Uvea ⁵²

Melanoma of Eye ¹²

Uveal Melanoma ⁵²

Eye Melanoma ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Skin diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:1752

EFO ¹⁷ EFO_1000403

UMLS ⁷¹ C0558356

Sources

Summaries for Ocular Melanoma

NIH Rare Diseases : ⁵² Intraocular melanoma is a cancer of the pigment-producing cells (melanocytes) in the middle layer of the eye, called the uveal tract . The uveal tract has 3 main parts: (1) the choroid (the tissue layer filled with blood vessels); (2) the ciliary body (the ring of muscle tissue that changes the size of the pupil and the shape of the lens); and (3) the iris (the colored part of the eye). Most cases (90%) of intraocular melanoma develop in the choroid, called choroidal melanoma; the ciliary body is less commonly a site of origin, and the iris is the least common. Each manifests with different clinical features and symptoms. Treatment depends on the site of origin (choroid, ciliary body, or iris), size and location of the tumor , the age of the individual, and other factors.

MalaCards based summary : Ocular Melanoma, also known as intraocular melanoma, is related to malignant spindle cell melanoma and skin melanoma. An important gene associated with Ocular Melanoma is PDCD6 (Programmed Cell Death 6), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and PI3K-Akt signaling pathway. The drugs Ranibizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and retina, and related phenotypes are cellular and homeostasis/metabolism

Disease Ontology : ¹² An ocular cancer that has material basis in melanocytes and is located in the eye.

Wikipedia : ⁷⁴ Uveal melanoma is a cancer (melanoma) of the eye involving the iris, ciliary body, or choroid... more...

Sources

Related Diseases for Ocular Melanoma

Diseases related to Ocular Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 419)

#	Related Disease	Score	Top Affiliating Genes
1	malignant spindle cell melanoma	30.9	NRAS KIT CDKN2A
2	skin melanoma	30.8	NRAS MC1R KIT CDKN2A CD63
3	malignant peritoneal mesothelioma	30.3	CDKN2A BAP1
4	plasmacytoma	30.2	VEGFA IL2 CDKN2A
5	exanthem	30.2	VEGFA TNF KIT IL2
6	rubeosis iridis	30.1	VEGFA PLG
7	peritoneal mesothelioma	30.0	VEGFA CDKN2A BAP1
8	cystitis	29.9	VEGFA TNF KIT IL2
9	thymoma	29.9	VEGFA TNF KIT IL2 CDKN2A
10	melanoma, cutaneous malignant 1	29.8	TERT NRAS MC1R KIT CDKN2A BRCA2
11	neurofibroma	29.8	VEGFA S100B KIT CDKN2A
12	leiomyosarcoma	29.8	VEGFA S100B KIT CDKN2A
13	retinal ischemia	29.8	VEGFA TNF HSPA4
14	uveal disease	29.7	VEGFA TNF NRAS IL2 BAP1
15	lung cancer susceptibility 3	29.6	VEGFA TERT NRAS KIT CDKN2A AXL
16	meningioma, familial	29.5	VEGFA TERT CDKN2A BAP1
17	adenocarcinoma	29.4	VEGFA KIT CDKN2A BRCA2 AXL
18	endophthalmitis	29.4	VEGFA TNF PLG
19	ocular cancer	29.4	PLG MC1R IL2 CDKN2A BRCA2
20	conjunctivitis	29.3	TNF PLG IL2
21	basal cell carcinoma	29.1	VEGFA TNF TERT MC1R KIT IL2
22	glioblastoma multiforme	29.1	VEGFA TERT NRAS KIT IL2 CDKN2A
23	myelodysplastic syndrome	29.0	VEGFA TNF TERT NRAS KIT IL2
24	mucosal melanoma	29.0	VEGFA TERT NRAS KIT IL2 CDKN2A
25	leukemia, chronic myeloid	28.8	VEGFA NRAS KIT HSPA4 AXL
26	gastric adenocarcinoma	28.8	VEGFA TNF TERT NRAS KIT CDKN2A
27	melanoma	28.7	VEGFA TNF TERT S100B NRAS MC1R
28	lymphoma, non-hodgkin, familial	28.7	VEGFA TNF NRAS IL2 HSPA4 CDKN2A
29	pancreatic adenocarcinoma	28.6	VEGFA TNF TERT KIT IL2 CDKN2A
30	neuroblastoma	28.5	VEGFA TNF TERT NRAS KIT IL2
31	leukemia, acute myeloid	28.3	VEGFA TNF TERT NRAS KIT IL2
32	melanoma, uveal	28.2	VEGFA TERT S100B PTP4A3 PLG NRAS
33	hepatocellular carcinoma	27.8	VEGFA TNF TERT NRAS MAGEA3 MAGEA1
34	ovarian cancer	27.4	VEGFA TNF TERT PLG MAGEA1 KIT
35	lung cancer	26.5	VEGFA TNF TERT PLG NRAS MAGEA3
36	necrotic uveal melanoma	12.8
37	mixed cell uveal melanoma	12.5
38	spindle cell intraocular melanoma	12.4
39	tumor predisposition syndrome	11.9
40	bap1 tumor predisposition syndrome	11.9
41	uveal epithelioid cell melanoma	11.6
42	iris spindle cell melanoma	11.3
43	melanoma, cutaneous malignant 10	10.9
44	severe combined immunodeficiency	10.5
45	melphalan allergy	10.5	NRAS IL2
46	macular retinal edema	10.5
47	cervical adenoid cystic carcinoma	10.5	KIT CDKN2A
48	malignant dermis tumor	10.4	NRAS KIT
49	malignant skin fibrous histiocytoma	10.4	NRAS KIT
50	laryngeal small cell carcinoma	10.4	KIT CDKN2A

Graphical network of the top 20 diseases related to Ocular Melanoma:

Sources

Symptoms & Phenotypes for Ocular Melanoma

MGI Mouse Phenotypes related to Ocular Melanoma:

⁴⁵ (show all 15)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.35	AXL BAP1 BRCA2 CDKN2A HSPA4 IL2
2	homeostasis/metabolism	MP:0005376	10.3	AXL BAP1 BRCA2 CD63 CDKN2A IL2
3	cardiovascular system	MP:0005385	10.29	AXL BAP1 CDKN2A IL2 KIT MC1R
4	endocrine/exocrine gland	MP:0005379	10.29	AXL BAP1 BRCA2 CDKN2A HSPA4 IL2
5	growth/size/body region	MP:0005378	10.27	BAP1 BRCA2 CDKN2A IL2 KIT MC1R
6	digestive/alimentary	MP:0005381	10.26	BAP1 BRCA2 CD63 CDKN2A IL2 KIT
7	hematopoietic system	MP:0005397	10.26	AXL BAP1 BRCA2 CDKN2A IL2 KIT
8	immune system	MP:0005387	10.21	AXL BAP1 BRCA2 CDKN2A IL2 KIT
9	integument	MP:0010771	10.14	AXL BAP1 BRCA2 CDKN2A KIT MC1R
10	mortality/aging	MP:0010768	10.13	AXL BAP1 BRCA2 CDKN2A HSPA4 IL2
11	neoplasm	MP:0002006	10.03	BAP1 BRCA2 CDKN2A IL2 KIT MC1R
12	liver/biliary system	MP:0005370	10.02	AXL CDKN2A IL2 KIT NRAS PLG
13	no phenotypic analysis	MP:0003012	9.81	BAP1 CDKN2A IL2 KIT MC1R NRAS
14	reproductive system	MP:0005389	9.7	AXL BAP1 BRCA2 CDKN2A HSPA4 IL2
15	respiratory system	MP:0005388	9.23	BAP1 CDKN2A IL2 KIT PLG TERT

Sources

Drugs & Therapeutics for Ocular Melanoma

Drugs for Ocular Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Ranibizumab

Approved

Phase 4

347396-82-1

459903

Triamcinolone

Approved, Vet_approved

Phase 4

124-94-7

31307

Hormone Antagonists

Phase 4

Hormones

Phase 4

Triamcinolone diacetate

Phase 4

triamcinolone acetonide

Phase 4

glucocorticoids

Phase 4

Triamcinolone hexacetonide

Phase 4

Anti-Inflammatory Agents

Phase 4

Melphalan

Approved

Phase 3

148-82-3

460612 4053

Bevacizumab

Approved, Investigational

Phase 3

216974-75-3

Fotemustine

Investigational

Phase 3

92118-27-9

Liver Extracts

Phase 3

Immunologic Factors

Phase 3

Immunosuppressive Agents

Phase 3

Alkylating Agents

Phase 3

Mitogens

Phase 3

Endothelial Growth Factors

Phase 3

Vaccines

Phase 3

Sodium citrate

Approved, Investigational

Phase 2

68-04-2

Tamoxifen

Approved

Phase 2

10540-29-1

2733526

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239 406563

Sargramostim

Approved, Investigational

Phase 2

83869-56-1, 123774-72-1

Ethiodized oil

Approved, Investigational

Phase 2

8008-53-5

Vincristine

Approved, Investigational

Phase 2

57-22-7, 2068-78-2

5978

Xylometazoline

Approved, Investigational

Phase 2

526-36-3

5709

Pasireotide

Approved

Phase 2

396091-73-9

9941444

Everolimus

Approved

Phase 2

159351-69-6

70789204 6442177

Peginterferon alfa-2b

Approved

Phase 2

99210-65-8, 215647-85-1

Lomustine

Approved, Investigational

Phase 2

13010-47-4

3950

Leuprolide

Approved, Investigational

Phase 2

53714-56-0

657181 3911

Aluminum sulfate

Approved

Phase 2

10043-01-3

Aluminum hydroxide

Approved, Investigational

Phase 2

21645-51-2

Pancrelipase

Approved, Investigational

Phase 2

53608-75-6

Valproic acid

Approved, Investigational

Phase 2

99-66-1

3121

Dacarbazine

Approved, Investigational

Phase 2

4342-03-4

5351166

Niraparib

Approved, Investigational

Phase 2

1038915-60-4

24958200

Acyclovir

Approved

Phase 2

59277-89-3

2022

Olaparib

Approved

Phase 2

763113-22-0

23725625

Iodine

Approved, Investigational

Phase 2

7553-56-2

807

Temozolomide

Approved, Investigational

Phase 2

85622-93-1

5394

Acetaminophen

Approved

Phase 2

103-90-2

1983

Crizotinib

Approved

Phase 2

877399-52-5

11626560 10366136 10366137 10366138 10366139 10366140 10366141

Cobalt

Approved, Experimental

Phase 2

7440-48-4

104729

Promethazine

Approved, Investigational

Phase 2

60-87-7

4927

Diphenhydramine

Approved, Investigational

Phase 2

58-73-1, 147-24-0

3100

Lenalidomide

Approved

Phase 2

191732-72-6

216326

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Sunitinib

Approved, Investigational

Phase 2

557795-19-4, 341031-54-7

5329102

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Interventional clinical trials:

(show top 50) (show all 169)

#	Name	Status	NCT ID	Phase	Drugs
1	A Randomized Control Trial of Intravitreal Ranibizumab (Lucentis) for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy for Choroidal Melanoma	Unknown status	NCT00540930	Phase 4	Ranibizumab
2	Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy	Unknown status	NCT02379000	Phase 4	Triamcinolone Acetonide
3	Treatment Of Radiation Retinopathy Trial Subtitle: Treatment of Radiation Retinopathy; Influence of Lucentis® and Kenalog® on Radiation Retinopathy After Irradiation of Choroidal Melanoma.	Unknown status	NCT00811200	Phase 2, Phase 3	ranibizumab;triamcinolone acetonide
4	Collaborative Ocular Melanoma Study (COMS)	Unknown status	NCT00000124	Phase 3
5	A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)	Completed	NCT01974752	Phase 3	75mg selumetinib;placebo;Dacarbazine
6	A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver	Completed	NCT00324727	Phase 3	melphalan;regional chemotherapy;systemic chemotherapy
7	A NON-COMMERCIAL, MULTICENTER, RANDOMIZED, TWO-ARMED, OPEN-LABEL PHASE III STUDY TO EVALUATE THE ADJUVANT VACCINATION WITH TUMOR RNA-LOADED AUTOLOGOUS DENDRITIC CELLS VERSUS OBSERVATION OF PATIENTS WITH RESECTED MONOSOMY 3 UVEAL MELANOMA	Recruiting	NCT01983748	Phase 3
8	The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases	Recruiting	NCT01785316	Phase 3
9	A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma	Recruiting	NCT02678572	Phase 3
10	Randomized Phase III Study Comparing an Adjuvant Chemotherapy With Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma	Active, not recruiting	NCT02843386	Phase 3	Adjuvant chemotherapy by Fotemustin
11	Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-Vascular Endothelial Growth Factor in Patients Treated With Proton Therapy for a Large Choroidal Melanoma	Not yet recruiting	NCT03172299	Phase 3	Aflibercept Injection;False injection
12	Intravenous Versus Intra-Arterial Fotemustine Chemotherapy in Patients With Liver Metastases From Uveal Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group	Terminated	NCT00110123	Phase 3	fotemustine;isolated perfusion
13	Randomized Phase III Study Of Adjuvant Immunization With The NA17.A2 And Melanoma Differentiation Peptites In HLA-A2 Patients With Primary Ocular Melanoma At High Risk Of Relapse	Terminated	NCT00036816	Phase 3
14	A Phase II Pilot Trial of Sutent, Tamoxifen, and Cisplatin in Patients With High-Risk Ocular Melanoma	Unknown status	NCT00489944	Phase 2	cisplatin;sunitinib malate;tamoxifen citrate
15	Phase II Single-Center Study of Bevacizumab in Combination With Temozolomide in Patients With First-Line Metastatic Uveal Melanoma	Unknown status	NCT01217398	Phase 2	temozolomide
16	Randomized Phase II Study to Compare a Combination Therapy With Gemcitabine and Treosulfan Versus a Monotherapy as First-Line Chemotherapy for Patients With Metastatic Ocular Melanoma	Unknown status	NCT00168870	Phase 2	Gemcitabine;Treosulfan
17	A Randomized Discontinuation, Blinded, Placebo-Controlled Phase II Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma	Unknown status	NCT01377025	Phase 2	Placebo;Sorafenib;Sorafenib
18	A Phase II Trial of Pyrazoloacridine (NSC 366140, IND 36325) in Metastatic Cutaneous and Ocular Melanoma	Completed	NCT00003802	Phase 2	pyrazoloacridine
19	Phase II Trial Of Interferon-B In Patients With Metastatic Cutaneous Melanoma And Metastatic Ocular Melanoma	Completed	NCT00085306	Phase 2
20	A Phase 2 Study Of Weekly Infusion Nab-paclitaxel (Paclitaxel Protein-bound Particles for Injectable Suspension) In Patients With Unresectable And Metastatic Uveal Melanoma	Completed	NCT00738361	Phase 2	nab-paclitaxel
21	Phase II Study of gp100:209-217 (210M) Antigen and MART-1:26-35 (27L) Antigen Emulsified in Montanide ISA-51 in Patients With Metastatic Ocular Melanoma	Completed	NCT00020475	Phase 2	gp100 antigen;interleukin-2;MART-1 antigen;Montanide ISA-51
22	Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination	Completed	NCT02517736	Phase 2	Sorafenib at a dose of 800 mg / day
23	A Randomised Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma	Completed	NCT01551459	Phase 2	Dacarbazine;Sunitinib
24	A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma	Completed	NCT02363283	Phase 2	Glembatumumab Vedotin
25	Adjuvant Therapy for Patients With Primary Uveal Melanoma With Genetic Imbalance	Completed	NCT01100528	Phase 2	dacarbazine
26	Phase II Study of IMC-A12 in Metastatic Uveal Melanoma	Completed	NCT01413191	Phase 2
27	Immuno-embolization of Hepatic Artery With Granulocyte-macrophage Colony Stimulating Factor (GM-CSF)	Completed	NCT00661622	Phase 2	GM-CSF
28	A Phase 2 Study of Marqibo in Patients With Metastatic Uveal Melanoma	Completed	NCT00506142	Phase 2	Marqibo® (vincristine sulfate liposomes injection)
29	Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma	Completed	NCT01143402	Phase 2	Dacarbazine;Selumetinib;Temozolomide
30	A Phase II Study of the HSP Inhibitor STA-9090 in Metastatic Ocular Melanoma	Completed	NCT01200238	Phase 2	STA-9090
31	A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma	Completed	NCT01979523	Phase 2	Trametinib;Uprosertib
32	Open Label Phase II Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma	Completed	NCT01034787	Phase 2	CP-675,206
33	A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma	Completed	NCT01252251	Phase 2	RAD001 (Everolimus) and Pasireotide (SOM230) LAR
34	THE IPI - Multibasket Trial in Advanced Melanoma: Prospective Clinical Phase II Multibasket Study in Melanoma Patients With Advanced Disease (DeCOG MM-PAL11)	Completed	NCT01355120	Phase 2	Ipilimumab
35	Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) in Combination With Carboplatin and Paclitaxel in Patients With Metastatic Uveal Melanoma	Completed	NCT00329641	Phase 2	carboplatin;paclitaxel;sorafenib tosylate
36	A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan Followed by Temozolomide for Subjects With Unresectable Hepatic Metastases From Ocular Melanoma	Completed	NCT00062933	Phase 2
37	Vaccination With Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant in Patients With Advanced Melanoma	Completed	NCT00089206	Phase 2
38	A Phase II Study of Temozolomide (Temodar) and Peglated Interferon Alfa-2B (PEGIntron) in the Treatment of Advanced Melanoma	Completed	NCT00027742	Phase 2	temozolomide
39	A Randomized Phase II Study of Oral Lenalidomide (Revlimid [TM]), an Antiangiogenic and Immunomodulatory Agent, in Subjects With Stage IV Ocular Melanoma	Completed	NCT00109005	Phase 2	Revlimid
40	An Extended Dosing, Two-phase Study of MDX-010 as Monotherapy or in Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 VG in the Treatment of Subjects With Resected Stage III or Stage IV Melanoma	Completed	NCT00084656	Phase 2
41	A Phase II Trial of an Intradermally Administered MART-1gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Matured With a Cytokine Cocktail for Patients With Metastatic Melanoma	Completed	NCT00334776	Phase 2
42	Vaccination With Multiple Synthetic Melanoma Peptides Recognized by Helper T-Cells in Patients With Advanced Melanoma	Completed	NCT00089219	Phase 1, Phase 2
43	An Open-label Study Of MDX-010 In Combination With gp100 Peptides Emulsified With Montanide ISA 51 In The Treatment Of Patients With Stage IV Melanoma	Completed	NCT00032045	Phase 2
44	A Randomized Phase II Trial of a Vaccine Combining Tyrosinase/gp100 Peptides Emulsified With Montanide ISA 51 With and Without Interleukin-12 for Patients With Resected Stages III and IV Melanoma	Completed	NCT00003339	Phase 2
45	A Phase II Study of Temozolomide, Thalidomide, and Lomustine in the Treatment of Advanced Melanoma	Completed	NCT00072345	Phase 2	lomustine;temozolomide;thalidomide
46	Phase II Study of Pegylated Interferon and Thalidomide in Pretreated Metastatic Malignant Melanoma	Completed	NCT00238329	Phase 2	thalidomide
47	Study of the Modulatory Activity of an LHRH-Agonist (Leuprolide) on Melanoma Peptide Vaccines as Adjuvant Therapy in Melanoma Patients	Completed	NCT00254397	Phase 2	Leuprolide
48	A Phase I/II Study of Temozolamide and Thalidomide in the Treatment of Advanced Melanoma	Completed	NCT00005815	Phase 1, Phase 2	temozolomide;thalidomide
49	A Phase II Randomized Trial of a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With Interleukin-12 With Alum or GM-CSF for Patients With Resected Stages IIB/C, III and IV Melanoma	Completed	NCT00031733	Phase 2	alum adjuvant
50	MDX-CTLA4 Combined With IL-2 for Patients With Metastatic Melanoma	Completed	NCT00058279	Phase 1, Phase 2

Search NIH Clinical Center for Ocular Melanoma

Sources

Genetic Tests for Ocular Melanoma

Sources

Anatomical Context for Ocular Melanoma

The Foundational Model of Anatomy Ontology organs/tissues related to Ocular Melanoma:

¹⁹

Eye

MalaCards organs/tissues related to Ocular Melanoma:

⁴⁰

Eye, Liver, Retina, T Cells, Endothelial, Skin, Testes

Sources

Publications for Ocular Melanoma

Articles related to Ocular Melanoma:

(show top 50) (show all 1007)

#	Title	Authors	PMID	Year
1	Cancer-related diseases of the eye: the role of calcium and calcium-binding proteins. ⁶¹ ⁵⁴	Subramanian L...Polans AS	15336963	2004
2	Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells. ⁵⁴ ⁶¹	Radosevich M...Ono SJ	15326139	2004
3	Ocular melanoma is not associated with CDKN2A or MC1R variants--a population-based study. ⁶¹ ⁵⁴	Vajdic C...Hayward NK	12883368	2003
4	BRCA2 mutations in a population-based series of patients with ocular melanoma. ⁶¹ ⁵⁴	Scott RJ...Kricker A	12385017	2002
5	Expression of MAGE genes in ocular melanoma cell lines. ⁵⁴ ⁶¹	Chen PW...Ksander BR	9220316	1997
6	Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. ⁶¹	Schonfeld L...Kirstein MM	32564137	2020
7	Gene Expression Profiling Prognostication of Posterior Uveal Melanoma: Does Size Matter? ⁶¹	Binkley EM...Singh AD	32081600	2020
8	Bioresorbable, Miniaturized Porous Silicon Needles on a Flexible Water-Soluble Backing for Unobtrusive, Sustained Delivery of Chemotherapy. ⁶¹	Kim H...Lee CH	32401016	2020
9	AAPM recommendations on medical physics practices for ocular plaque brachytherapy: Report of task group 221. ⁶¹	Thomson RM...Melhus CS	31883269	2020
10	Practice Patterns for the Treatment of Uveal Melanoma with Iodine-125 Plaque Brachytherapy: Ocular Oncology Study Consortium Report 5. ⁶¹	Binder C...Skalet AH	32509767	2020
11	Electrochemotherapy in 3D Ocular Melanoma Spheroids using a Customized Electrode. ⁶¹	Fiorentzis M...Heinzelmann J	32421010	2020
12	The Collaborative Ocular Melanoma Study Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma. ⁶¹	Salowe R...O'Brien JM	32200814	2020
13	Ocular melanoma incidence rates and trends in the United States, 2001-2016. ⁶¹	Culp MB...Wu M	32350449	2020
14	Broadening risk profile in familial colorectal cancer type X; increased risk for five cancer types in the national Danish cohort. ⁶¹	Therkildsen C...Nilbert M	32321466	2020
15	The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma: IV. Local Treatment Failure and Enucleation in the First 5 Years after Brachytherapy. COMS Report No. 19. ⁶¹	Jampol LM...COMS Follow-up of Plaqued Eyes Working Group	32200815	2020
16	Risk of second primary cutaneous and noncutaneous melanoma after cutaneous melanoma diagnosis: A population-based study. ⁶¹	Beroukhim K...Eisen DB	31626886	2020
17	Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study. ⁶¹	Arzu Yasar H...Urun Y	30924738	2020
18	Neoadjuvant intravitreal ranibizumab treatment in high-risk ocular melanoma patients: a two-stage single-centre phase II single-arm study. ⁶¹	Hussain RN...Damato B	31425478	2020
19	Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples. ⁶¹	Toomey S...Hennessy BT	32087721	2020
20	Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization. ⁶¹	Levey AO...Kokabi N	31686137	2020
21	Meta-analysis on the utility of radiotherapy for the treatment of Ocular Melanoma ⁶¹	Messineo D...Pacella F	31916427	2020
22	BRCA1-associated protein (BAP1)-inactivated melanocytic tumors. ⁶¹	Zhang AJ...Duncan LM	31233225	2019
23	Experimental validation of a new COMS-like 24 mm eye plaque for the treatment of large ocular melanoma tumors. ⁶¹	McCauley Cutsinger S...Deufel CL	31444131	2019
24	Embolization of variant hepatic arteries in patients undergoing percutaneous hepatic perfusion for unresectable liver metastases from ocular melanoma. ⁶¹	Meijer TS...Burgmans MC	31650973	2019
25	m6A modification suppresses ocular melanoma through modulating HINT2 mRNA translation. ⁶¹	Jia R...Fan X	31722709	2019
26	CHOROIDAL NEVUS IMAGING FEATURES IN 3,806 CASES AND RISK FACTORS FOR TRANSFORMATION INTO MELANOMA IN 2,355 CASES: The 2020 Taylor R. Smith and Victor T. Curtin Lecture. ⁶¹	Shields CL...Shields JA	30608349	2019
27	CHOROIDAL NEVUS TRANSFORMATION INTO MELANOMA PER MILLIMETER INCREMENT IN THICKNESS USING MULTIMODAL IMAGING IN 2355 CASES: The 2019 Wendell L. Hughes Lecture. ⁶¹	Shields CL...Shields JA	30883534	2019
28	Delivered dose changes in COMS plaque-based ocular brachytherapy arising from vitrectomy with silicone oil replacement. ⁶¹	Morrison H...Weis E	31272841	2019
29	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). ⁶¹	Nathan P...Schadendorf D	31445199	2019
30	Clinical spectrum, treatment and outcomes of uveal melanoma in a tertiary centre. ⁶¹	Wong W...Gopal L	31197380	2019
31	An improved treatment planning and quality assurance process for Collaborative Ocular Melanoma Study eye plaque brachytherapy. ⁶¹	Weersink RA...Beiki-Ardakani A	31235445	2019
32	Multi-Modality Analysis Improves Survival Prediction in Enucleated Uveal Melanoma Patients. ⁶¹	Drabarek W...Rotterdam Ocular Melanoma Study Group	31425584	2019
33	Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. ⁶¹	Khoja L...Joshua AM	31150059	2019
34	Complications and adverse events of plaque brachytherapy for ocular melanoma. ⁶¹	Peddada KV...Verma V	31523242	2019
35	Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies. ⁶¹	Verma V...Welsh JW	31446147	2019
36	Comprehensive Characterization of the Human Endogenous Retrovirus HERV-K(HML-6) Group: Overview of Structure, Phylogeny, and Contribution to the Human Genome. ⁶¹	Pisano MP...Tramontano E	31167914	2019
37	Improvement of dose distribution in ocular brachytherapy with 125I seeds 20-mm COMS plaque followed to loading of choroidal tumor by gold nanoparticles. ⁶¹	Zabihzadeh M...Hoseini-Ghahfarokhi M	31169211	2019
38	Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial. ⁶¹	Meijer TS...Vahrmeijer AL	30767147	2019
39	Vitamin D receptors (VDR), hydroxylases CYP27B1 and CYP24A1 and retinoid-related orphan receptors (ROR) level in human uveal tract and ocular melanoma with different melanization levels. ⁶¹	Markiewicz A...Romanowska-Dixon B	31235702	2019
40	RELATIONSHIP OF CLINICAL FEATURES AND BASELINE TUMOR SIZE WITH GENE EXPRESSION PROFILE STATUS IN UVEAL MELANOMA: A Multi-institutional Study. ⁶¹	Berry D...Ocular Oncology Study Consortium	29578940	2019
41	Corneal Substructure Dosimetry Predicts Corneal Toxicity in Patients With Uveal Melanoma Treated With Proton Beam Therapy. ⁶¹	Lee HJ...Rengan R	30763658	2019
42	Y90 Clinical Data Update: Cholangiocarcinoma, Neuroendocrine Tumor, Melanoma, and Breast Cancer Metastatic Disease. ⁶¹	Padia SA	31079715	2019
43	Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma. ⁶¹	Dean MK...Samuels SE	30797699	2019
44	Natural killer cells and pigment epithelial-derived factor control the infiltrative and nodular growth of hepatic metastases in an Orthotopic murine model of ocular melanoma. ⁶¹	Jones NM...Grossniklaus HE	31117965	2019
45	Small choroidal melanoma: detection with multimodal imaging and management with plaque radiotherapy or AU-011 nanoparticle therapy. ⁶¹	Shields CL...Shields JA	30844944	2019
46	Epidemiological evidence of carcinogenicity of sunbed use and of efficacy of preventive measures. ⁶¹	Gandini S...Boniol M	30811691	2019
47	Skin cancer and welding. ⁶¹	Falcone LM...Zeidler-Erdely PC	30280417	2019
48	An Update on Mucosal Melanoma: Future Directions. ⁶¹	Goldemberg DC...de Melo AC	31032785	2019
49	A comparison of the shielding effectiveness of silicone oil vitreous substitutes when used with Palladium-103 and Iodine-125 eye plaques. ⁶¹	Yang YM...Lamb JM	30554429	2019
50	Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. ⁶¹	Keilholz U...Gulley JL	30651126	2019

Sources

Genes for Ocular Melanoma

Genes related to Ocular Melanoma (0 elite genes):

(show all 22)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	PDCD6	Programmed Cell Death 6	Protein Coding	18.19	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	15336963
2	MAGEA3	MAGE Family Member A3	Protein Coding	17.8	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	9220316
3	MAGEA1	MAGE Family Member A1	Protein Coding	17.5	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	9220316
4	MC1R	Melanocortin 1 Receptor	Protein Coding	16.63	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	12883368
5	CD63	CD63 Molecule	Protein Coding	14.99	GeneCards inferred via : Publications Gene name (show sections)
6	BAP1	BRCA1 Associated Protein 1	Protein Coding	13.39	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	13.19	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	12385017
8	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	12.76	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	12.5	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	IL2	Interleukin 2	Protein Coding	12.13	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	11.74	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	11.52	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	TERT	Telomerase Reverse Transcriptase	Protein Coding	10.6	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	PTP4A3	Protein Tyrosine Phosphatase 4A3	Protein Coding	10.4	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	TNF	Tumor Necrosis Factor	Protein Coding	10.26	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	RFC5	Replication Factor C Subunit 5	Protein Coding	10.17	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	S100B	S100 Calcium Binding Protein B	Protein Coding	10.16	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	AXL	AXL Receptor Tyrosine Kinase	Protein Coding	10.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	HSPA4	Heat Shock Protein Family A (Hsp70) Member 4	Protein Coding	9.92	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	PLG	Plasminogen	Protein Coding	9.71	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	PDGFRB	Platelet Derived Growth Factor Receptor Beta	Protein Coding	9.65	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	VTN	Vitronectin	Protein Coding	9.48	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Ocular Melanoma

Cosmic variations for Ocular Melanoma:

⁹

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM84060431	GNA11	eye,uveal tract,malignant melanoma,ring	c.626A>T	p.Q209L	19:3118944-3118944	24

Sources

Expression for Ocular Melanoma

Search GEO for disease gene expression data for Ocular Melanoma.

Sources

Pathways for Ocular Melanoma

Pathways related to Ocular Melanoma according to GeneCards Suite gene sharing:

(show all 13)

#	Super pathways	Score	Top Affiliating Genes
1	Nanog in Mammalian ESC Pluripotency ⁶³ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶³ eNOS Signaling ⁶³ GSK3 Signaling ⁶³	13	VEGFA TNF NRAS KIT IL2 HSPA4
2	PI3K-Akt signaling pathway ³⁶ Show member pathways Human papillomavirus infection ³⁶	12.68	VEGFA TNF TERT NRAS KIT IL2
3	Gastric cancer ³⁶ Show member pathways Breast cancer ³⁶ Hepatocellular carcinoma ³⁶	12.54	TERT NRAS KIT CDKN2A BRCA2
4	Proteoglycans in cancer ³⁶	12.07	VEGFA TNF NRAS CD63
5	NF-kappaB Signaling ⁴	12.07	TNF MAGEA3 KIT IL2 CD63
6	Pathways in cancer ³⁶	11.89	VEGFA TERT NRAS KIT IL2 CDKN2A
7	Human T-cell leukemia virus 1 infection ³⁶	11.69	TNF TERT NRAS IL2 CDKN2A
8	Innate Lymphoid Cells Differentiation ⁶⁴	11.6	TNF KIT IL2
9	Dendritic Cells Developmental Lineage Pathway ⁶⁴	11.56	TNF KIT IL2
10	Bladder cancer ³⁶ ¹	11.53	VEGFA NRAS CDKN2A
11	Photodynamic therapy-induced NF-kB survival signaling ¹ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.41	VEGFA TNF IL2
12	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.21	TNF IL2 CDKN2A
13	Aryl Hydrocarbon Receptor ¹	11.11	VEGFA TNF NRAS

Sources

GO Terms for Ocular Melanoma

Cellular components related to Ocular Melanoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.56	VEGFA TNF S100B PLG KIT IL2
2	cell surface	GO:0009986	9.1	VEGFA TNF PLG KIT CD63 AXL

Biological processes related to Ocular Melanoma according to GeneCards Suite gene sharing:

(show all 17)

#	Name	GO ID	Score	Top Affiliating Genes
1	MAPK cascade	GO:0000165	9.87	TNF NRAS KIT IL2
2	activation of cysteine-type endopeptidase activity involved in apoptotic process	GO:0006919	9.73	TNF PDCD6 CDKN2A
3	negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	GO:0043154	9.7	VEGFA TNF MAGEA3
4	positive regulation of protein kinase B signaling	GO:0051897	9.67	TNF MC1R KIT AXL
5	positive regulation of kinase activity	GO:0033674	9.63	KIT IL2 AXL
6	positive regulation of endothelial cell proliferation	GO:0001938	9.61	VEGFA PDCD6 NRAS
7	positive regulation of MAP kinase activity	GO:0043406	9.58	VEGFA TNF KIT
8	replicative senescence	GO:0090399	9.55	TERT CDKN2A
9	positive regulation of vascular permeability	GO:0043117	9.54	VEGFA PTP4A3
10	negative regulation of cell-cell adhesion mediated by cadherin	GO:2000048	9.51	VEGFA PLG
11	positive regulation of protein kinase C signaling	GO:0090037	9.49	VEGFA MC1R
12	somatic stem cell division	GO:0048103	9.48	KIT CDKN2A
13	regulation of vascular endothelial growth factor signaling pathway	GO:1900746	9.32	PTP4A3 CD63
14	establishment of protein localization to telomere	GO:0070200	9.26	TERT BRCA2
15	vascular endothelial growth factor receptor-2 signaling pathway	GO:0036324	9.16	VEGFA PDCD6
16	pigmentation	GO:0043473	9.13	MC1R KIT CD63
17	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	8.92	VEGFA TNF KIT IL2

Molecular functions related to Ocular Melanoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:0005515	9.62	VEGFA TNF TERT S100B RFC5 PTP4A3

Sources

Sources for Ocular Melanoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia